New onset diabetes after transplantation (NODAT): an overview
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Although renal transplantation ameliorates cardiovascular risk factors by restoring renal function, it introduces new cardiovascular risks including impaired glucose tolerance or diabetes mellitus, hypertension, and dyslipidemia that are derived, in part, from immunosuppressive medications such as calcineurin inhibitors, corticosteroids, or mammalian target of rapamycin inhibitors. New onset diabetes mellitus after transplantation (NODAT) is a serious and common complication following solid organ transplantation. NODAT has been reported to occur in 2% to 53% of all solid organ transplants. Kidney transplant recipients who develop NODAT have variably been reported to be at increased risk of fatal and nonfatal cardiovascular events and other adverse outcomes including infection, reduced patient survival, graft rejection, and accelerated graft loss compared with those who do not develop diabetes. Identification of high-risk patients and implementation of measures to reduce the development of NODAT may improve long-term patient and graft outcome. The following article presents an overview of the literature on the current diagnostic criteria for NODAT, its incidence after solid organ transplantation, suggested risk factors and potential pathogenic mechanisms. The impact of NODAT on patient and allograft outcomes and suggested guidelines for early identification and management of NODAT will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Effect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737 · cited 1×
“This finding has not yet been validated in either transplant recipients or prospective trials in the general population.(61) Similarly, data regarding direct renin inhibition on NODAT are lacking.”
BackgroundHeisel, O., Heisel, R., Balshaw, R., & Keown, P. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00372.x · Cited by 506
Cited by
Branched-chain amino acids in metabolic signalling and insulin resistance
Lynch, C. J., & Adams, S. H. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.171 · Cited by 1,461
Neuberger, J. M., Bechstein, W. O., Kuypers, D. R. J., Burra, P., Citterio, F., De Geest, S., Duvoux, C., Jardine, A. G., Kamar, N., Krämer, B. K., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001651 · Cited by 315
Novel views on new-onset diabetes after transplantation: development, prevention and treatment
Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs583 · Cited by 120
Galvin, Z., Rajakumar, R., Chen, E., Adeyi, O., Selzner, M., Grant, D., Sapisochin, G., Greig, P., Cattral, M., McGilvray, I., et al. (2019) · Liver Transplantation · doi:10.1002/lt.25338 · Cited by 76
Pham Vu, T., Nguyen Thi Thuy, D., Truong Quy, K., Nguyen Thi Thu, H., Nguyen Van, D., Diem Thi, V., Do Manh, H., Nguyen Trung, K., Do, Q., Tran Viet, T., et al. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101392 · Cited by 13
Sood (2016) · Experimental and Clinical Transplantation · doi:10.6002/ect.2015.0295 · Cited by 9
Metadata
- Authors
- Pham, P.-T., Pham, P.-M., & Pham, P.-C.
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-05
- Volume
- 4
- Pages
- 175
- ISSN
- 1178-7007 (ISSN-L)
- OpenAlex
- W1999249353
- Cited by
- 243
- References
- 4
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.